David Mountcastle Sells 5,177 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 5,177 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $23.15, for a total transaction of $119,847.55. Following the completion of the transaction, the chief financial officer owned 167,732 shares of the company’s stock, valued at approximately $3,882,995.80. This trade represents a 2.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

David Mountcastle also recently made the following trade(s):

• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total transaction of $133,134.36.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total transaction of $192,809.85.
• On Friday, December 12th, David Mountcastle sold 23,887 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total value of $597,891.61.

Privia Health Group Trading Down 3.6%

NASDAQ:PRVA traded down $0.83 during trading hours on Tuesday, hitting $22.47. 1,025,433 shares of the company were exchanged, compared to its average volume of 813,068. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 132.18, a price-to-earnings-growth ratio of 1.49 and a beta of 0.82. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51. The company has a fifty day simple moving average of $23.03 and a 200 day simple moving average of $23.60.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.21. The firm had revenue of $541.17 million for the quarter, compared to analyst estimates of $516.61 million. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The business’s revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.21 EPS. Equities research analysts predict that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of Privia Health Group

Several large investors have recently made changes to their positions in the company. Bayban acquired a new position in Privia Health Group during the 4th quarter worth approximately $26,000. Hantz Financial Services Inc. grew its position in Privia Health Group by 456.2% in the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after purchasing an additional 926 shares during the period. Global Retirement Partners LLC grew its position in Privia Health Group by 579.8% in the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock valued at $38,000 after purchasing an additional 1,351 shares during the period. Canada Pension Plan Investment Board increased its stake in Privia Health Group by 48.0% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in Privia Health Group during the 4th quarter valued at $93,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on PRVA shares. BMO Capital Markets began coverage on shares of Privia Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $30.00 target price for the company. Truist Financial raised their target price on Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Barclays lifted their target price on Privia Health Group from $22.00 to $23.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. JPMorgan Chase & Co. boosted their price target on Privia Health Group from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Finally, Royal Bank Of Canada assumed coverage on shares of Privia Health Group in a research report on Friday, January 9th. They set an “outperform” rating and a $31.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Privia Health Group has a consensus rating of “Moderate Buy” and an average price target of $31.00.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.